CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and the fifth largest cord blood banks globally. CryoHoldco is also many times larger than any other stem cell bank in Latin America, with over 400,000 stem cell units in storage.
Hematopoietic Stem Cells (HSCs)
Do You Know the Top Quality Guarantees Among U.S. Cord Blood Banks?
Private cord blood banking continues to evolve in the United States, with several large companies offering storage of newborn stem cells for potential medical use by families. As of late 2025, Cord Blood Registry (CBR) remains the largest U.S. private cord blood bank, having stored more than one million cord blood and cord tissue units, making it significantly larger than many competitors and a clear industry leader.
In addition to CBR, other prominent private cord blood banks in the U.S. include ViaCord, Cryo-Cell International, and Americord Registry. These banks vary in experience, storage scale, services offered, and the specifics of their quality guarantee programs.
Cord Blood Industry Trends – Clinical Trials, Publications, Patents, Grants, & More
With the global cord blood banking industry maturing and consolidating over the past five years, it is more important than ever to be well-educated about cord blood industry trends. There are now fewer market players, because numerous small cord blood banks have either been acquired or gone out of business.
However, this era of maturation and consolidation has had as many benefits to surviving cord blood banks as drawbacks. On average, the remaining market participants are now larger, stronger, better capitalized, and storing larger quantities of cord blood and tissue units than when the market was more fragmented.
Market Forces Affecting the Cord Blood and Cord Tissue Industry
Recently released, the “Global Cord Blood & Tissue Banking Industry Report – Market Size, Segmentation, and Forecasts” explores clinical trial market data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue. Within this rapidly evolving marketplace, those who choose to commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage.
Because the global cord blood banking industry has matured substantially over the past few years, new market forces have created both serious threats and novel opportunities. [Read more…]
Cord Blood Processing Method PrepaCyte-CB Leads in Engraftment Time
The cord blood processing method PrepaCyte-CB has been shown to engraft more quickly during the vital stage of post-transplant recovery than any other processing method. At the 15th Annual International Cord Blood Symposium in San Diego, California, in June 2017, the St. Louis Cord Blood Bank presented the median time it took patients infused with cord blood using either its Hetastarch or PrepaCyte-CB processing method to reach an absolute neutrophil count (ANC) of 500.
PrepaCyte-CB was found to engraft a full four days more quickly than the Hetastarch processing method (16 days versus 20 days) and has shown to be just as safe to the patient.1 Combining this data with those of other public data sources, PrepaCyte-CB was found to engraft more quickly than any other processing method. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 28
- Next Page »